-

06:19:43 PM

ANVS Stock News

ANVS - Annovis Bio Inc

01/25/23 7:30 AM

NYSE : ANVS

clinical triallow float

ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE

Annovis Bio, Inc., a clinical-stage drug platform company addressing neurodegenerative diseases, today provided a patient enrollment update for the Company's ongoing Phase 3 study of buntanetap for the treatment of Parkinson's disease. Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: "We are very pleased with the pace of enrollment...

RHEA-AI

neutral

01/06/23 7:30 AM

NYSE : ANVS

managementlow float

Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice

RHEA-AI

very positive

11/08/22 5:35 PM

NYSE : ANVS

low float

Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent

RHEA-AI

neutral

10/20/22 7:30 AM

NYSE : ANVS

conferenceslow float

Annovis Bio to Present at the 2022 ThinkEquity Investor Conference

(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the ThinkEquity 2022 Investor Conference on Wednesday, October 26, 2022, in New

RHEA-AI

neutral

10/11/22 7:30 AM

NYSE : ANVS

clinical triallow float

Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today announced the publication of Phase 2a clinical study data in The Journal of Prevention of Alzheimer's

RHEA-AI

neutral

10/06/22 7:30 AM

NYSE : ANVS

clinical triallow float

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of

RHEA-AI

very positive

09/29/22 7:30 AM

NYSE : ANVS

conferenceslow float

Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference

(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29,

RHEA-AI

neutral

09/13/22 7:30 AM

NYSE : ANVS

low float

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today the publication of three granted US patents – US11400075 ( link), US11376238 ( link), and US11382893 (

RHEA-AI

neutral

09/08/22 7:30 AM

NYSE : ANVS

low float

Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today released the following letter to stockholders from its Chief Executive Officer Dr. Maria

RHEA-AI

neutral

08/29/22 4:00 PM

NYSE : ANVS

managementlow float

Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately. Mr. Hagopian

RHEA-AI

very positive

ANVS Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.annovisbio.com
CeoMaria Maccecchini
Security nameAnnovis Bio Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2
Tags
- Electronic Equipment/Instruments
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1055 Westlakes Dr Ste 300
StatePennsylvania
CityBerwyn
Zip19312-2410
CountryUS
Phone16107273913

About Annovis Bio Inc

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). The Comapny's believes that it is the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The Company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. The Company has two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients.